JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Lipid disturbances induced by psychotropic drugs: clinical and genetic predictors for early worsening of lipid levels and new-onset dyslipidaemia in Swiss psychiatric samples

  • 0Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, Lausanne, Switzerland; and Les Toises Psychiatry and Psychotherapy Center, Lausanne, Switzerland.
Bjpsych Open +

|

December 5, 2024

|

December 5, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Early worsening of plasma lipid levels (EWL) in patients on psychotropic drugs can be predicted by clinical and genetic factors. Identifying these risks helps manage dyslipidemia development.

Area Of Science

  • Pharmacogenomics
  • Cardiovascular Risk Assessment
  • Psychiatric Pharmacology

Background

  • Early worsening of plasma lipid levels (EWL) after initiating psychotropic treatments predicts long-term lipid abnormalities and dyslipidemia.
  • Identifying predictive factors for EWL is crucial for proactive patient management.

Purpose Of The Study

  • To identify clinical and genetic risk factors that predict early worsening of plasma lipid levels (EWL) in patients starting psychotropic treatments.

Main Methods

  • Evaluated baseline clinical characteristics and dyslipidemia-associated single nucleotide polymorphisms (SNPs) for EWL prediction.
  • Used a discovery sample (n=177) and two replication samples (n1=176, n2=86) from the PsyMetab cohort.

Main Results

  • Low baseline total cholesterol, LDL-C, triglycerides, and high HDL-C predicted EWL.
  • Incorporating genetic parameters (SNPs) significantly improved the prediction of EWL for total cholesterol, LDL-C, HDL-C, and triglycerides (AUCs improved to 0.87-0.92).
  • Genetic factors enhanced prediction of new-onset dyslipidemia for total cholesterol, LDL-C, and HDL-C in combined samples.

Conclusions

  • Both clinical and genetic factors are significant predictors of EWL and new-onset dyslipidemia in patients on at-risk psychotropic treatments.
  • Further research with larger cohorts is needed to refine SNP estimates for clinical predictive models.

Keywords:

Related Concept Videos

Mania and Antimanic Drugs: Overview 01:24

135

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...

Human Genetics 01:28

534

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...

Psychosis and Antipsychotic Drugs: Overview 01:28

176

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...

Psychosis: Goals of Pharmacotherapy 01:26

103

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.

Bipolar Disorder 01:30

54

Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders 01:27

453

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...